Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)

  1. Ocio, E.
  2. Perrot, A.
  3. Bories, P.
  4. San-Miguel, J.F.
  5. Blau, I.W.
  6. Karlin, L.
  7. Martínez-López, J.
  8. Pönisch, W.
  9. Bringhen, S.
  10. Marcatti, M.
  11. Mateos, M.-V.
  12. Rodríguez-Otero, P.
  13. LeRoux, N.
  14. Dong, Y.
  15. Macé, S.
  16. Fitzmaurice, T.
  17. Moreau, P.
Aldizkaria:
Clinical Lymphoma, Myeloma and Leukemia

ISSN: 2152-2669,  2152-2650

Argitalpen urtea: 2022

Alea: 22

Zenbakia: 6

Orrialdeak: 425

Mota: Hutsen zuzenketa

DOI: 10.1016/J.CLML.2022.03.010 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus